-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Pemvidutide (ALT-801)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemvidutide in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Type 2 Diabetes Drug Details: Pemvidutide (ALT-801) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemvidutide in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Obesity Drug Details: Pemvidutide (ALT-801) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) Drug Details: Pemvidutide (ALT-801) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6084 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6084 in Hepatitis B report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6084 in Hepatitis B Drug Details: RG-6084 (RO-7191863) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HepTcell in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HepTcell in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HepTcell in Hepatitis B Drug Details: FP-02 (Hepsyn-B, HepTcell) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemvidutide in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Obesity Drug Details: Pemvidutide (ALT-801) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemvidutide in Non Alcoholic Fatty Liver Disease (NAFLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemvidutide in Non Alcoholic Fatty Liver Disease (NAFLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemvidutide in Non Alcoholic Fatty Liver Disease (NAFLD)...
-
Company Insights
Innovation and Patenting activity of Altimmune Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Altimmune Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Company Profile
Altimmune Inc – Company Profile
Altimmune Inc (Altimmune), is a biopharmaceutical company that includes the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s pipeline products include ALT-801, a glucagon receptor to treat metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). Altimmune also offers nasovax, an intranasally administered recombinant influenza vaccine and heptcell, an immunotherapy to patients chronically infected with the hepatitis B virus; nasoshield, a vaccine for the prevention of anthrax disease, inhalation of pathogen spores. It find...
Add to Basket